Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Blood Cancer J ; 5: e340, 2015 Aug 21.
Artigo em Inglês | MEDLINE | ID: mdl-26295610

RESUMO

Preclinical and emerging clinical studies demonstrate that bispecific T-cell engaging (BiTE) antibody constructs can potently lyse targeted tumor cells, but the determinants for their activity remain incompletely understood. Using human acute myeloid leukemia (AML) cell lines engineered to overexpress individual T-cell ligands, we found that expression of the inhibitory ligands, PD-L1 and PD-L2, reduced the cytolytic activity of the BiTE antibody construct targeting CD33, AMG 330; conversely, expression of the activating ligands, CD80 and CD86, augmented the cytotoxic activity of AMG 330. Consistent with these findings, treatment with an activating antibody directed at the co-stimulatory T-cell receptor, CD28, significantly increased AMG 330-induced cytotoxicity in human AML cell lines. Using specimens from 12 patients with newly diagnosed or relapsed/refractory AML, we found that activation of CD28 also increased the activity of AMG 330 in primary human AML cells (P=0.023). Together, our findings indicate that T-cell ligands and co-receptors modulate the anti-tumor activity of the CD33/CD3 BiTE antibody construct, AMG 330. These findings suggest that such ligands/co-receptors could serve as biomarkers of response and that co-treatment strategies with pharmacological modulators of T-cell receptor signaling could be utilized to further enhance the activity of this targeted therapeutic.


Assuntos
Anticorpos Biespecíficos/farmacologia , Antineoplásicos/farmacologia , Linfócitos T/fisiologia , Citotoxicidade Celular Dependente de Anticorpos , Antígenos CD28/agonistas , Antígenos CD28/metabolismo , Complexo CD3/metabolismo , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Leucemia Mieloide Aguda/tratamento farmacológico , Ligantes , Lectina 3 Semelhante a Ig de Ligação ao Ácido Siálico/metabolismo , Linfócitos T/efeitos dos fármacos , Células Tumorais Cultivadas
2.
Leukemia ; 28(10): 1969-77, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24721792

RESUMO

Recent technological advances led to an appreciation of the genetic complexity of human acute myeloid leukemia (AML), but underlying progenitor cells remain poorly understood because their rarity precludes direct study. We developed a co-culture method integrating hypoxia, aryl hydrocarbon receptor inhibition and micro-environmental support via human endothelial cells to isolate these cells. X-chromosome inactivation studies of the least mature precursors derived following prolonged culture of CD34(+)/CD33(-) cells revealed polyclonal growth in highly curable AMLs, suggesting that mutations necessary for clonal expansion were acquired in more mature progenitors. Consistently, in core-binding factor (CBF) leukemias with known complementing mutations, immature precursors derived following prolonged culture of CD34(+)/CD33(-) cells harbored neither mutation or the CBF mutation alone, whereas more mature precursors often carried both mutations. These results were in contrast to those with leukemias with poor prognosis that showed clonal dominance in the least mature precursors. These data indicate heterogeneity among progenitors in human AML that may have prognostic and therapeutic implications.


Assuntos
Células-Tronco Hematopoéticas/citologia , Leucemia Mieloide Aguda/genética , Mutação , Antígenos CD34/metabolismo , Hipóxia Celular , Separação Celular , Técnicas de Cocultura , Fatores de Ligação ao Core/metabolismo , Citometria de Fluxo , Sistema Hematopoético , Humanos , Leucemia Mieloide Aguda/metabolismo , Prognóstico , Receptores de Hidrocarboneto Arílico/metabolismo , Lectina 3 Semelhante a Ig de Ligação ao Ácido Siálico/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA